MaxCyte, Inc MXCT 深 滬
等待開盤 12-23 09:30:00 美东时间
1.63
+0.130
+8.67%
華盛通- 最 高1.65
- 今 開1.51
- 成交量 81.02万股
- 最 低 1.50
- 昨 收 1.50
- 總市值 1.74亿
- 52周最高 5.20
- 市盈率 靜 --
- 換手率 0.76%
- 52周最低 1.26
- 委 比 -88.44%
- 總股本 1.07亿
- 歷史最高 17.44
- 量 比 0.82
- 振 幅 10.00%
- 歷史最低 1.26
- 每 手 1
- 風險率 1.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MaxCyte CFO Douglas Swirsky To Transition From Role In H1 2026
MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today
11-13 05:17
MaxCyte Q3 EPS $(0.12) Misses $(0.11) Estimate, Sales $6.829M Miss $8.370M Estimate
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 9.09 percent decrease over losses of $(0.11) per share from the same
11-13 05:09
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
MaxCyte Reports Preliminary Q3 Revenue of $6.8M And Reiterates Its 2025 Revenue Guidance
MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its preliminary results for the third quarter ended September 30, 2025 and reiterated its 2025 revenue g
11-05 21:24
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
MaxCyte Signs Strategic Platform License Agreement With Moonlight Bio To Advance T Cell Therapy Development
MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today
10-06 20:07
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
MaxCyte Inc. has signed a Strategic Platform License agreement with Moonlight Bio to support the development of T cell therapies using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. Moonlight Bio aims to improve outcomes for solid tumor treatments. MaxCyte will receive licensing fees and program-related revenue.
10-06 12:05
MaxCyte Announces Major Workforce Reduction Plan
MaxCyte ( ($MXCT) ) has shared an announcement. On September 22, 2025, MaxCyte,...
09-23 04:59
MaxCyte announces 34% workforce reduction to cut costs
MaxCyte (NASDAQ:MXCT) is implementing a restructuring plan that includes a 34% reduction in its global workforce, including EOR personnel. The move is aimed at cutting operating expenses, streamlining...
09-23 04:36
MaxCyte Restructures Operations, Reduces Global Workforce By 34% To Unlock ~$13.6M In Annual Savings
MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today
09-23 04:33
